Loss-of-function genetic diseases and the concept of pharmaceutical targets [1]

Nature Reviews Genetics

Volumn 8, Issue 5, 2007, Pages

  Segalat L ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

CAENORHABDITIS ELEGANS; CHANNELOPATHY; DIABETES MELLITUS; DROSOPHILA MELANOGASTER; DRUG MECHANISM; DRUG TARGETING; EXPERIMENTAL MOUSE; GENE FUNCTION; GENETIC DISORDER; GENETIC REGULATION; HEART FAILURE; HUMAN; HYPERTENSION; LETTER; MENTAL DISEASE; METABOLIC DISORDER; MONOGENIC DISORDER; NONHUMAN; OBESITY; ORGAN SIZE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROSTATE HYPERTROPHY;

EID: 34247276447     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Brinkman, R. R., Dube, M. P., Rouleau, G. A., Orr, A. C. & Samuels, M. E. Human monogenic disorders - a source of novel drug targets. Nature Rev. Genet. 7, 249-260 (2006).
2. Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
3. Overington, J. P, Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993-996 (2006).
4. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353-359 (2004).
5. Van der Schyf, C. J., Geldenhuys, W. J. & Youdim, M. B. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem. 99, 1033-1048 (2006).
6. Peltonen, L., Perola, M., Naukkarinen, J. & Palotie, A. Lessons from studying monogenic disease for common disease. Hum. Mol. Genet. 15, R67-R74 (2006).
7. Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Rev. Drug Discov. 2, 38-51 (2003).